Entrada Therapeutics, Inc. Common Stock (TRDA)

Price$6.58

Value ScoreC

Growth ScoreF

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-46.45%

Price vs S&P 500 (4W)-62.79%

VGM Score27.76

Market Capitalization$257.77M

P/E Ratio (Annual)7.40x

All Metrics

Book Value / Share (Quarterly)$6.98

P/TBV (Annual)1.80x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-3.39

Price vs S&P 500 (YTD)-46.80%

Net Profit Margin (TTM)-2895.05%

EPS (TTM)$-4.00

10-Day Avg Trading Volume0.37M

EPS Excl Extra (TTM)$-4.00

EPS (Annual)$-3.47

ROI (Annual)-46.96%

Cash / Share (Quarterly)$6.57

Revenue Growth QoQ (YoY)-95.74%

P/E Normalized (Annual)7.40x

ROA (Last FY)-38.09%

Revenue Growth TTM (YoY)-96.67%

EBITD / Share (TTM)$-4.20

ROE (5Y Avg)-19.21%

Operating Margin (TTM)-3109.29%

Cash Flow / Share (Annual)$-3.38

P/B Ratio0.95x

P/B Ratio (Quarterly)1.78x

Net Income / Employee (Annual)$-945,700

EV / Revenue (TTM)31.60x

Net Interest Coverage (TTM)-1704.33x

ROA (TTM)-42.20%

EV / EBITDA (TTM)25.46x

EPS Incl Extra (Annual)$-3.47

Current Ratio (Annual)12.53x

Quick Ratio (Quarterly)13.32x

3-Month Avg Trading Volume0.32M

52-Week Price Return-18.43%

Revenue / Employee (TTM)$37,800

Tangible BV / Share (Quarterly)$7.40

P/S Ratio (Annual)10.14x

Asset Turnover (Annual)0.07x

52-Week High$16.45

EPS Excl Extra (Annual)$-3.47

CapEx CAGR (5Y)-14.88%

26-Week Price Return-32.86%

Quick Ratio (Annual)12.17x

13-Week Price Return-43.15%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)13.90x

Enterprise Value$181.32M

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$167,200

Pretax Margin (Annual)-561.84%

Cash / Share (Annual)$7.72

3-Month Return Std Dev130.00%

Net Income / Employee (TTM)$-1,092,900

ROE (Last FY)-46.96%

EPS Basic Excl Extra (Annual)$-3.47

P/FCF (TTM)3.45x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-4.00

ROI (TTM)-51.22%

P/S Ratio (TTM)44.92x

Revenue / Share (Annual)$0.61

Tangible BV / Share (Annual)$6.77

Price vs S&P 500 (52W)-46.58%

Year-to-Date Return-35.41%

5-Day Price Return0.15%

EPS Normalized (Annual)$-3.47

ROA (5Y Avg)-16.26%

Net Profit Margin (Annual)-565.48%

Month-to-Date Return-6.08%

Cash Flow / Share (TTM)$-0.58

EBITD / Share (Annual)$-3.72

Operating Margin (Annual)-621.13%

ROI (5Y Avg)-19.21%

EPS Basic Excl Extra (TTM)$-4.00

P/TBV (Quarterly)1.55x

P/B Ratio (Annual)1.28x

Pretax Margin (TTM)-2878.29%

Book Value / Share (Annual)$8.00

Price vs S&P 500 (13W)-53.81%

Beta-0.28x

P/FCF (Annual)1.92x

Revenue / Share (TTM)$0.14

ROE (TTM)-51.22%

52-Week Low$4.93

vGradeC

gGradeF

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.95est. -1.06

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.25

4.31

4.29

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
TRDAEntrada Therapeutics, Inc. Common Stock	C	F	D	$6.58
LLYEli Lilly & Co.	D	B	B	$1078.78
JNJJohnson & Johnson	C	C	C	$223.24
ABBVABBVIE INC.	D	C	C	$217.13
MRKMerck & Co., Inc.	C	C	C	$114.70
AZNAstraZeneca PLC	D	B	C	$176.28
NVSNovartis AG	C	C	C	$143.66
NVONovo-Nordisk A/S	B	B	B	$42.00
ABTAbbott Laboratories	C	C	D	$86.99
PFEPfizer Inc.	B	C	C	$25.34
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$32.83

About

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing medicines to treat neuromuscular and ocular diseases using its proprietary Endosomal Escape Vehicle (EEV) platform, which enables efficient delivery of therapeutic molecules into cells. The company's pipeline focuses on oligonucleotide therapies for Duchenne muscular dystrophy through multiple exon-skipping approaches, and includes a partnered program for myotonic dystrophy type 1. By targeting previously inaccessible intracellular sites, Entrada aims to improve therapeutic efficacy for serious genetic diseases.